Publications
Detailed Information
Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheong, Teak-Chin | - |
dc.contributor.author | Shin, Ji-Young | - |
dc.contributor.author | Chun, Kyung-Hee | - |
dc.date.accessioned | 2012-06-11T02:14:13Z | - |
dc.date.available | 2012-06-11T02:14:13Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.citation | CANCER SCIENCE; Vol.101 1; 94-102 | ko_KR |
dc.identifier.issn | 1347-9032 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76943 | - |
dc.description.abstract | Galectin-3 is known to modulate cell proliferation and apoptosis and is highly expressed in human cancers, but its function in gastric cancer is still controversial. Here, we examined the role of galectin-3 in gastric cancer cells by silencing it with synthetic double-stranded siRNA. After silencing of galectin-3, cell numbers decreased and cell shape changed. Galectin-3 siRNA treatment also induced G(1) arrest. DNA microarray analysis was used to assess changes in gene expression following galectin-3 silencing. We found that silencing of galectin-3 caused changes in gene expression. RT-PCR and real-time PCR were utilized for validation of the changes found in microarray studies. Western blot analysis confirmed changes in the expression of proteins of interest: cyclin D1, survivin, XIAP, XAF, PUMA, and GADD45 alpha. Generally, it tended to increase the expression of several pro-apoptotic genes, and to decrease the expression of cell cycle progressive genes. We also confirmed that changes in the expression of these genes were caused by galectin-3 overexpression. Finally, we demonstrated that silencing of galectin-3 enhanced apoptosis induction with chemotherapeutic agents by further reducing the expression of anti-apoptotic and/or cell survival molecules such as survivin, cyclin D1, and XIAP, and increasing the expression of pro-apoptotic XAF-1. We conclude that galectin-3 is involved in cancer progression and malignancy by modulating the expression of several relevant genes, and inhibition of galectin-3 may be an approach to improve chemotherapy of gastric cancers. (Cancer Sci 2009). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.title | Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 정택진 | - |
dc.contributor.AlternativeAuthor | 신지영 | - |
dc.contributor.AlternativeAuthor | 전경희 | - |
dc.identifier.doi | 10.1111/j.1349-7006.2009.01364.x | - |
dc.citation.journaltitle | CANCER SCIENCE | - |
dc.description.citedreference | Connolly K, 2009, CANCER CHEMOTH PHARM, V64, P307, DOI 10.1007/s00280-008-0872-x | - |
dc.description.citedreference | Wang Y, 2009, AM J PATHOL, V174, P1515, DOI 10.2353/ajpath.2009.080816 | - |
dc.description.citedreference | Lin CI, 2009, BIOCHEM BIOPH RES CO, V379, P626, DOI 10.1016/j.bbrc.2008.12.153 | - |
dc.description.citedreference | Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746 | - |
dc.description.citedreference | Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036 | - |
dc.description.citedreference | Nangia-Makker P, 2007, CANCER RES, V67, P11760, DOI 10.1158/0008-5472.CAN-07-3233 | - |
dc.description.citedreference | Nakahara S, 2007, CANCER METAST REV, V26, P605, DOI 10.1007/s10555-007-9095-6 | - |
dc.description.citedreference | Tsuboi K, 2007, ANTICANCER RES, V27, P2289 | - |
dc.description.citedreference | Ahmed H, 2007, BIOCHEM BIOPH RES CO, V358, P241, DOI 10.1016/j.bbrc.2007.04.114 | - |
dc.description.citedreference | Lopes RB, 2007, INT J CANCER, V120, P2344, DOI 10.1002/ijc.22554 | - |
dc.description.citedreference | Fukumori T, 2007, DRUG RESIST UPDATE, V10, P101, DOI 10.1016/j.drup.2007.04.001 | - |
dc.description.citedreference | Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469 | - |
dc.description.citedreference | Wang TT, 2007, WORLD J GASTROENTERO, V13, P2784 | - |
dc.description.citedreference | Nangia-Makker P, 2007, J BIOENERG BIOMEMBR, V39, P79, DOI 10.1007/s10863-006-9063-9 | - |
dc.description.citedreference | Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795 | - |
dc.description.citedreference | Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020 | - |
dc.description.citedreference | Okada K, 2006, ANTICANCER RES, V26, P1369 | - |
dc.description.citedreference | Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179 | - |
dc.description.citedreference | Mazurek N, 2005, CANCER RES, V65, P10767, DOI 10.1158/0008-5472.CAN-04-3333 | - |
dc.description.citedreference | Rodel F, 2005, CANCER RES, V65, P4881 | - |
dc.description.citedreference | Shimura T, 2005, CANCER RES, V65, P3535 | - |
dc.description.citedreference | Tong QS, 2005, CANCER GENE THER, V12, P509, DOI 10.1038/sj.cgt.7700813 | - |
dc.description.citedreference | Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496 | - |
dc.description.citedreference | Shimura T, 2004, CANCER RES, V64, P6363 | - |
dc.description.citedreference | Puglisi F, 2004, CANCER LETT, V212, P233, DOI 10.1016/j.canlet.2004.03.006 | - |
dc.description.citedreference | Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013 | - |
dc.description.citedreference | Choi JH, 2004, CANCER BIOL THER, V3, P447 | - |
dc.description.citedreference | Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786 | - |
dc.description.citedreference | Krzeslak A, 2004, CELL MOL BIOL LETT, V9, P305 | - |
dc.description.citedreference | Yu J, 2003, CANCER CELL, V4, P248 | - |
dc.description.citedreference | Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237 | - |
dc.description.citedreference | Miyazaki J, 2002, ONCOL REP, V9, P1307 | - |
dc.description.citedreference | Song YK, 2002, AM J PATHOL, V160, P1069 | - |
dc.description.citedreference | Ikeguchi M, 2002, APOPTOSIS, V7, P23 | - |
dc.description.citedreference | Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595 | - |
dc.description.citedreference | Shin S, 2001, BIOCHEMISTRY-US, V40, P1117 | - |
dc.description.citedreference | Baldus SE, 2000, TUMOR BIOL, V21, P258 | - |
dc.description.citedreference | Matarrese P, 2000, INT J CANCER, V85, P545 | - |
dc.description.citedreference | Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43 | - |
dc.description.citedreference | Idikio H, 1998, INT J ONCOL, V12, P1287 | - |
dc.description.citedreference | Akahani S, 1997, CANCER RES, V57, P5272 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.